Arrowhead Pharmaceuticals (ARWR) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) recently:

• 11/26/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $45.00 to $48.00. They now have an “equal weight” rating on the stock.
• 11/20/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at The Goldman Sachs Group, Inc. from $27.00 to $48.00. They now have a “neutral” rating on the stock.
• 11/19/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at Royal Bank Of Canada from $45.00 to $52.00. They now have an “outperform” rating on the stock.
• 11/19/2025 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
• 11/19/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at Piper Sandler from $45.00 to $70.00. They now have an “overweight” rating on the stock.
• 11/12/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $29.00 to $45.00. They now have an “equal weight” rating on the stock.
• 10/8/2025 – Arrowhead Pharmaceuticals had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/8/2025 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.

Insider Activity

In other news, insider James C. Hamilton sold 20,000 shares of the stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. Following the completion of the sale, the insider owned 212,122 shares in the company, valued at approximately $7,424,270. This represents a 8.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 50,000 shares of company stock valued at $1,525,000 over the last quarter. 4.30% of the stock is currently owned by corporate insiders.

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.